Cytisine

Drug Profile

Cytisine

Alternative Names: Tabex

Latest Information Update: 01 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sopharma
  • Developer Achieve Life Sciences
  • Class Alkaloids; Antiparkinsonians; Neuroprotectants
  • Mechanism of Action Alpha4 beta2 nicotinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Smoking withdrawal

Highest Development Phases

  • Phase III Smoking withdrawal

Most Recent Events

  • 26 Oct 2017 Sopharma and Achieve Life Sciences sign a manufacturing and supply agreement for cytisine API and tablets
  • 04 Oct 2017 Achieve plans a phase III trial for Smoking withdrawal in USA in mid-2018
  • 04 Oct 2017 Achieve Life Sciences completes enrolment in a clinical bioavailability trial in Smoking withdrawal in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top